Following on from my post yesterday about GSK making affordable drugs for third world countries by lifting patents on specific new medicines, it is great to see a new report showing figures that could save the EU & US $110 Billion through 2020! This will mean money back in tax payers pockets and hopefully more money pumped back into the development of new products.
Biosimilars are the future of the Pharmaceutical world and it's a very exciting time for both well established companies and small start ups alike.
With 56 new biosimilars in clinical development, IMS Consulting Group says in a new report that the biologic competitors could save health systems across Europe and the US as much as $110 billion through 2020. But the savings for both regions will vary considerably as payers have adopted a variety of approaches to encourage physicians to prescribe biosimilars, motivate manufacturers and require certain clinical evidence to support the prescribing of these treatments.